2. Vías de señalización
  3. Cytoskeleton
  4. Integrin
  5. α4β7 Isoform

α4β7

α4β7 integrin is a lymphocyte adhesion receptor that mediates binding to MAdCAM-1 and supports selective lymphocyte homing to gut-associated lymphoid tissue[1]. Mechanistically, α4β7 enables rolling adhesion under flow and ligand-dependent conformational activation, linking integrin structure to intestinal immune-cell trafficking[2]. In disease models, T cell-associated α4β7, but not α4β1, drives chronic colitis, while antibody-secreting cells depend on α4β7/MAdCAM-1 for intestinal recruitment and microbiota control[3][4]. Compared with related isoforms, α4β7 chiefly supports intestinal homing through MAdCAM-1, whereas α4β1 associates with VCAM-1 and αEβ7 supports epithelial retention through E-cadherin[2][4]. For experimental and translational applications, vedolizumab selectively antagonizes α4β7 and showed induction and maintenance efficacy in ulcerative colitis and Crohn’s disease trials[5][6].

Productos relacionados con α4β7 (17):

Cat. No. Nombre del producto Efecto Pureza
  • HY-107589
    BIO5192
    		Inhibitor 99.96%
    BIO5192 is a selective and potent integrin α4β1 (VLA-4) inhibitor (Kd<10 pM). BIO5192 selectively binds to α4β1 (IC50=1.8 nM) over a range of other integrins. BIO5192 results in a 30-fold increase in mobilization of murine hematopoietic stem and progenitors (HSPCs) over basal levels.
  • HY-P9984
    Etrolizumab
    		Inhibitor 99.56%
    Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD).
  • HY-15770
    TR-14035
    		Antagonist 99.87%
    TR-14035 is a orally active dual α4β7/α4β1 integrin antagonist, with IC50 s of 7 nM and 87 nM for α4β7 and α4β1, respectively. TR-14035 can be used for the research of inflammation and autoimmune diseases.
  • HY-14951
    Firategrast
    		Antagonist 99.75%
    Firategrast (SB 683699) is an orally active and specific α4β1/α4β7 integrin antagonist. Firategrast reduces trafficking of lymphocytes into the central nervous system (CNS) and decreases multiple sclerosis (MS) activity.
  • HY-14126
    BIO-1211
    		Inhibitor 99.64%
    BIO-1211 is a highly selective and orally active α4β1 (VLA-4) inhibitor, with IC50 values of 4 nM and 2 μM for α4β1 and α4β7, respectively.
  • HY-185350
    α4β7 Integrin-IN-2
    		Inhibitor
    α4β7 Integrin-IN-2 is an inhibitor of human α4β7 integrin with an IC50 <5 nM. α4β7 Integrin-IN-2 modulates α4β7 integrin-mediated biological pathways. α4β7 Integrin-IN-2 can be used for the research of inflammatory dieases.
  • HY-186079
    Deethyl-emvistegrast
    		Inhibitor
    Deethyl-emvistegrast is a quinoline derivative and also a α4β7 integrin inhibitor. Deethyl-emvistegrast is the hydrolytic product of Emvistegrast (HY-177080). Deethyl-emvistegrast modulates inflammatory pathways. Deethyl-emvistegrast can be used in research related to inflammatory bowel disease (Crohn's disease and ulcerative colitis).
  • HY-177961
    α4β7 Integrin-IN-1
    		Inhibitor
    α4β7 Integrin-IN-1 (Example 356) is a potent inhibitor of α4β7 integrin (integrin). Its ability to block the interaction between α4β7 integrin and MadCAM-1 (EC50) is 0.05 nM. α4β7 Integrin-IN-1 can be used for the study of inflammatory bowel disease.
  • HY-107589A
    BIO5192 hydrate
    		Inhibitor 99.96%
    BIO5192 hydrate is a selective and potent integrin α4β1 (VLA-4) inhibitor (Kd<10 pM). BIO5192 hydrate selectively binds to α4β1 (IC50=1.8 nM) over a range of other integrins. BIO5192 hydrate results in a 30-fold increase in mobilization of murine hematopoietic stem and progenitors (HSPCs) over basal levels.
  • HY-177080
    Emvistegrast
    		Antagonist 98.06%
    Emvistegrast (GS-1427) is a quinolone derivative. Emvistegrast is also an inhibitor of α4β7 integrin. Emvistegrast can be used to investigate diseases mediated by α4β7 integrin, such as inflammatory bowel disease.
  • HY-138542
    RO0270608
    		Antagonist 98.80%
    RO0270608, the active metabolite of R411, is a dual alpha4beta1-alpha4beta7 (α4β1/α4β7) integrin antagonist. Antiinflammatory activity.
  • HY-114225
    TBC-4746
    		Antagonist
    TBC-4746 is a α4β1/α4β7 integrin antagonist. TBC-4746 can be used in the research of asthma and multiple sclerosis.
  • HY-177080A
    (S,R)-Emvistegrast
    		Control
    (S,R)-Emvistegrast ((S,R)-GS-1427) is an isomer of Emvistegrast (HY-177080). (S,R)-Emvistegrast is an integrin α4β7 inhibtor.
  • HY-159179
    α4 integrin receptor antagonist 3
    		Inhibitor
    α4 integrin receptor antagonist 3 (Compound 11) is an orally active α4integrin receptor antagonist. α4 integrin receptor antagonist 3 can inhibit the adhesion of K562 cells mediated by the interaction between α4β1/VCAM-1 and α4β7/MAdCAM-1, with IC50 values of 130 nM and 2 nM, respectively. α4 integrin receptor antagonist 3 has the potential to be used in the study of dextran sulfate sodium (DSS) colitis mouse model.
  • HY-177080B
    Emvistegrast axial isomer
    Emvistegrast (GS-1427) axial isomer is an axial isomer of Emvistegrast (HY-177080). Emvistegrast axial isomer is an integrin α4β7 inhibtor.
  • HY-14189
    Valategrast hydrochloride
    		Antagonist
    Valategrast hydrochloride (R-411) is a potent integrin α4β1 (VLA-4) and α4β7 dual antagonist. Valategrast hydrochloride has the potential for Chronic obstructive pulmonary disease (COPD) and asthma treatment.
  • HY-186079A
    (S)-Deethyl-emvistegrast
    		Inhibitor
    (S)-Deethyl-emvistegrast is the S-enantiomer of Deethyl-emvistegrast (HY-186079). Deethyl-emvistegrast is a quinoline derivative and also a α4β7 integrin inhibitor. It acts as the hydrolysis product of Emvistegrast (HY-177080). Deethyl-emvistegrast modulates inflammatory pathways and can be used in research related to inflammatory bowel diseases (Crohn's disease and ulcerative colitis).